To complement the initial findings, we expanded the GSEA-based analysis to identify significantly upregulated or downregulated pathways in ROS1+ lung adenocarcinomas and cell lines in comparison to ALK/RET+ tumor samples (Figure 1F). The gene discussed is ALK; the disease is lung adenocarcinoma.